1177 / 1816
Prognostic signatures for the predictions of late
distant recurrence
19-9-2017
I Sestak
These markers combine expression profiles of a panel of cancer-related genes
Mostly been developed and validated in ER+/HER2- and Node- patients
Prognostic information or recurrence-free survival independent of traditional clinical markers (TNM)
They were not developed to specifically predict late (distant) recurrences